Categorización del riesgo cardiorenal en DM2

Referencias bibliográficas

  1. Berg DD, Wiviott SD, Scirica BM, Gurmu Y, et al. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 Nov 5;140(19):1569-1577.
  2. Blonde L, Umpierrez G, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive CarePland2022 Update. Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002.
  3. Cannistraci R, Mazzetti S, Mortara A, Perseghin G, Ciardullo S. Risk stratification tools for heart failure in the diabetes clinic. Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1070-1079.
  4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.
  5. De Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Oct 3: dci220027. Disponible en: https://diabetesjournals.org/care/article/doi/10.2337/dci22-0027/147614/DiabetesManagement-in-Chronic-Kidney-Disease-A
  6. Delgado C, Baweja M, Burrows NR, Crews DC, et al. Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report From the NKF-ASN Task Force. Am J Kidney Dis. 2021 Jul;78(1):103-115.
  7. Delgado C, Baweja M, Crews DC, Eneanya ND, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2021 Sep 22: S0272-6386(21)00828-3.
  8. Delgado C, Baweja M, Crews DC, Eneanya ND, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Supplemental Methods for Performance in External Validation (Bias, Precision and Accuracy). [internet]. USA. ajkd.org. citado: 15-11-2021. Disponible en: https://www.ajkd.org/cms/10.1053/j.ajkd.2021.08.003/attachment/411c47a7-c000-4350-b369-929979e85e2f/mmc1.pdf
  9. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supplement_1): S140-S157. Disponible en: https://diabetesjournals.org/care/issue/46/Supplement_1
  10. ElSayed NA, Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supplement_1): S191-S202. Disponible en: https://diabetesjournals.org/care/issue/46/Supplement_1
  11. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supplement_1): S140-S157. Disponible en: https://diabetesjournals.org/care/issue/46/Supplement_1
  12. ElSayed NA, Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supplement_1): S191-S202. Disponible en: https://diabetesjournals.org/care/issue/46/Supplement_1
  13. Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022 Mar 16;21(1):42. Disponible en: https://cardiab.biomedcentral.com/articles/10.1186/s12933-022-01474-z
  14. Giugliano D, Maiorino MI, Bellastella G, et al. The residual cardiorenal risk in type 2 diabetes. Cardiovasc Diabetol. 2021 Feb 5;20(1):36. doi: 10.1186/s12933-021-01229-2.
  15. National Kidney foundation. eGFR Calculator. [internet]. New York, NY. 2021. Citado: 15-11-2021. Disponible en: https://www.kidney.org/professionals/kdoqi/gfr_calculator
  16. Pop-Busui R, Januzzi J, Bruemmer D, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022 Jul 7;45(7):1670-1690. Disponible en: https://diabetesjournals.org/care/article/45/7/1670/147048/Heart-Failure-An-Underappreciated-Complication-of
  17. Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C A, et al. A comprehensive approach to type 2 diabetes mellitus. Endocrinol Diabetes Nutr (Engl Ed). 2019 Aug-Sep;66(7):443-458. Epub 2019 Feb 28. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S2530016419300229?%20via%3Dihub
  18. Rossing P, Caramori L, C.N. Chan J, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S): S1-S127. doi: 10.1016/j.kint.2022.06.008
  19. TIMI STUDY GROUP. TIMI Risk Score for HF in Diabetes [internet]. Boston, MA. Citado 15-11-2021. Disponible en: https://timi.org/timi-risk-score-for-hf-in-diabetes/
  20. Verma S, Sharma A, Kanumilli N, Butler J. Predictors of heart failure development in type 2 diabetes: a practical approach. Curr Opin Cardiol. 2019;34(5):578-583.
  21. Verma S, Sharma A, Zinman B, Ofstad AP, et al. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020 Jul;22(7):1141-1150.
  22. Visseren FLJ, Mach F, Smulders YM, Carballo D, et al; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. PMID: 34458905.
  23. Zinman B, M.D., Wanner C, M.D., John M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Cerrar